Tony Piscopio is an OnKure co-founder and has served as Chief Executive Officer and a member of the OnKure Board of Directors since its founding in April, 2011. Dr. Piscopio is a serial entrepreneur with executive leadership experience spanning a 23 year career in the life sciences industry. Most recently, he served as Board Chairman and Chief Executive Officer at Chemizon, Inc., a global drug discovery organization where he was responsible for managing operations in the U.S., Seoul, Korea, and Beijing, China, and oversaw the acquisition of the company to Taihan Electric Wire Co. after two years of operation.

Prior to this, Dr. Piscopio co-founded Array BioPharma (ARRY;NASDAQ) where he served as V.P. of Chemistry and was responsible for strategy, new product development, GMP manufacturing, process research, parallel synthesis on an industrial scale and oncology drug discovery. Prior to founding Array, Dr. Piscopio was a founding member of Amgen’s small molecule drug discovery division, Boulder, CO, and served as a research scientist at Pfizer. Dr. Piscopio was an NIH Postdoctoral Fellow at The Scripps Research Institute and received his Ph.D. at the University of Wisconsin-Madison.

Xuedong Liu is a Professor of Chemistry and Biochemistry at the University of Colorado-Boulder. He received his Ph.D. in Genetics from the University of Wisconsin-Madison in 1994 with Professor Janet Mertz at McArdle Laboratory for Cancer Research. From 1995 to 2000, he was an NIH and DOD postdoctoral fellow at the Whitehead Institute for Biomedical Research with Professor Harvey F. Lodish at Massachusetts Institute of Technology. He has been on faculty of the University of Colorado-Boulder since 2000.

Professor Liu’s research interests include the biochemistry and systems biology of cell signaling. He focuses on understanding signal transduction mechanism of growth factors and small molecule ligands in normal and cancer cells. His laboratory also works on deciphering molecular mechanisms of neurodegenerative disorders such as Parkinson’s disease. Professor Liu has authored or co-authored more than 75 research papers and patents and is the coeditor of a book entitled “Computational Modeling of Signaling Networks”. In addition, Professsor Liu is an OnKure co-founder and is responsible for the developing the profile-specific histone deacetylase inhibitor platform which forms the basis of OnKure’s technology. Professor Liu is the recipient of Inventor of the Year Award in 2013 from the University of Colorado.

S. Gail Eckhardt, MD is Professor and Head of the Division of Medical Oncology at the University of Colorado Denver and Health Sciences Center where she also holds the Stapp/Harlow Endowed Chair for Cancer Research.

After graduating from the University of Texas Medical Branch in Galveston, Dr. Eckhardt completed her internship and residency at the University of Virginia Medical Center. After a post-doctoral fellowship at the Scripps Research Foundation, she completed her training in medical oncology at the University of California at San Diego.

Following fellowship, Dr. Eckhardt joined the faculty of the Cancer Therapy and Research Center, Institute for Drug Development in San Antonio, Texas, where she held the position of Associate Director of Clinical Research. In 1999, Dr. Eckhardt joined the faculty of the University of Colorado School of Medicine to establish a Phase I program. In 2004 she became the Director of the Developmental Center.

Dr. Eckhardt has served on numerous committees/study sections, including the ASCO Molecular Oncology Task Force, the ASCO Board of Directors, the FDA Oncology Drugs Advisory Committee, and the NCI Developmental Therapeutics Study Section. She is also a member of two NCI Steering Committees: Gastrointestinal and Investigational Drugs. In addition, Dr. Eckhardt has been an Associate Editor of Clinical Cancer Research, the Journal of Clinical Oncology, and Investigational New Drugs. Therapeutics Program in the University of Colorado Cancer Center.

Dr. Eckhardt is the Principal Investigator on three NIH grants involving early clinical trials, mentoring, and colorectal cancer research and has conducted numerous phase I and II clinical trials. She has published over 70 manuscripts and serves on numerous advisory boards. Her area of interest is in the preclinical and clinical development of combinations of molecularly targeted compounds, with a laboratory focus on colorectal cancer.

Dr. Baskin graduated from Swarthmore College with high honors in the Division of Natural Sciences and Engineering. He attended the Mt. Sinai School of Medicine in New York, where he graduated first in his class, and received the James Felt Prize for the highest overall performance during the four years of medical school training.

He then received his surgical and neurosurgical training at the University of California in San Francisco. Dr. Baskin began his research career while still a resident at the University of California San Francisco (UCSF). In 1982, he spent a year as a Research Associate at the University of Capetown Medical School and Groote Schuur Hospital in Capetown, South Africa. The following year, Dr. Baskin returned to UCSF and served as a Research Associate in the Hormone Research Laboratory. Based on novel research demonstrating ways to restore brain function, he won the American Academy of Neurosurgery Award for the best research performed by a neurosurgery resident.

After completing his residency, Dr. Baskin was appointed as Assistant Professor of Neurological Surgery and Assistant Professor of the Center for Biotechnology at Baylor College of Medicine, with a joint appointment as Chief of Neurological Surgery at the VA Hospital. In 1994 he was promoted to Professor at Baylor College of Medicine in the departments of Neurosurgery and Anesthesiology, positions he held until 2005 when his academic career transitioned to Houston Methodist.

Dr. Gore joined the University of Colorado School of Medicine faculty as an Assistant Professor in July 2001. She trained in Pediatrics at Children’s National Medical Center and the University of Colorado. She completed her fellowship training in pediatric hematology/oncology/bone marrow transplantation at the University of Colorado Cancer Center and Children’s Hospital Colorado.

Dr. Gore is a member of the Developmental Therapeutics (phase I clinical trials) Program, where she also directs the Early Phase Hematological Malignancies Program. These comprehensive programs include multidisciplinary cancer clinics, tumor boards, and research endeavors. She is the founder and the Program Leader of the Experimental Therapeutics Program at Children’s Hospital Colorado.

She co-founded and co-directs the Pediatric Oncology Experimental Therapeutics Investigators’ Consortium (POETIC) and collaborates regularly with European Investigators on international phase I oncology studies. Dr. Gore’s primary interests are in leukemias and sarcomas. She has received funding from the National Cancer Institute, the Leukemia and Lymphoma Society, Alex’s Lemonade Stand, and numerous foundation awards. She has more than 65 publications of her work and has lectured extensively nationally and internationally.